Fox Chase Cancer Center
To refer a patient call 888-FOX-CHASE (888-369-2427)
To refer a patient call 800-TEMPLE-MED (877-589-0013)
Featured Items |view more
Join us for this in-person educational program, presented by Fox Chase Cancer Center and the Temple Health Office for Continuing Medical Education. The program will cover the latest strategies for optimally managing localized and advanced ...
“Even when I was four, I wanted to be a clinician; I’d sit with my grandpa, listen to his ailments, and write prescriptions for him in Russian,” says Elena Dreyzin, PA-C., an advanced practice provider in the Fox Chase Cancer Center Department of Urology.
Why does immunotherapy work for some bladder cancer patients and fail for others?
Fox Chase Cancer Center and Temple Health are pleased to announce the new Fox Chase-Temple Urologic Institute, a groundbreaking initiative that will concentrate on both benign and oncologic urology.
A Fox Chase study ends up on the cover Journal of Urology cover by revealing a hidden danger in cystic renal masses.
Join Steve Sterious, MD FACS , Fox Chase-Temple Urologic Institute Provider, to discuss Aquablation and the changing surgical landscape of BPH.
Dr. Joshua Cohn, Fox Chase-Temple Urologic Institute Provider, discusses urinary incontinence in women, focusing on the etiology, prevalence and diagnostic evaluation. He also discusses the various treatment options that may be most helpful for each patient.
Centralizing scientific discovery, advanced research, and clinical care—all for a new therapeutic pathway.
Could NanoKnife be the future of prostate cancer care?
A Life-Saving Idea for Bladder Cancer Patients.
Bladder removal is life-altering. This study examines when and why some patients may not need it.
View this symposium presented by Fox Chase Cancer Center and the Temple Health Office for Continuing Medical Education. Learn the most current strategies for optimally managing localized and advanced prostate cancer from the Fox Chase ...
Adaptive radiation therapy allows clinicians to make daily adjustments in a patient’s treatment in real time while the patient is on the treatment table based on the cancer’s response to the radiation, position of the tumor, and the location ...
Built on strength: world-class specialists, innovative researchers, and clinical leaders.
Fighting for life everywhere she goes.
The artificial urinary sphincter is an implantable device designed to treat incontinence in prostate cancer survivors. The device has existed for 50 years, and in that time, best practices around its use have undergone several paradigm shifts.
Digging into the "why" of racial disparity in kidney cancer outcomes.
Daniel Eun, MD, Fox Chase-Temple Urologic Institute Provider, provides an overview of buccal mucosa graft ureteroplasty procedure and pointers for providers looking to learn how to perfom.
Complications post surgery can include the development of pelvic lymphoceles which patients may present infection or external leaks. Daniel Eun, MD, Fox Chase-Temple Urologic Institute Provider, discusses how to avoid and manage lymphoceles ...
Daniel Eun, MD, Michael Metro, MD, and other Fox Chase-Temple Urologic Institute Providers present a 53-year-old patient diagnosed with bilateral ureteral strictures from tuberculosis who undergoes a bilateral ureteral reconstruction.
Amoroso is part of the nurse-led dedicated intravesical clinic that helps optimize treatment for patients and workflow for other physicians and nurses.
Researchers at Fox Chase Cancer Center have developed a model that predicts disease recurrence and survival in patients with intermediate- and high-risk localized kidney cancer more accurately than existing prognostic models.
Fox Chase’s Alexander Kutikov, MD, FACS, is leading an international effort to create a centralized, streamlined, point-of-care resource for the management of adrenal masses.
Fox Chase Cancer Center’s urologic oncology group shares an educational video that provides instruction on how to perform a device-free, free-handed transperineal prostate biopsy.
Two new collaborative publications focus on treatment decisions for patients with renal masses.
Three members of Fox Chase Cancer Center’s Genitourinary Cancer Program – Elizabeth Plimack, MD, MS; Alexander Kutikov, MD, FACS; and Benjamin Miron, MD -- have gained national recognition for their work advancing the care of patients ...
As patient care adapted to the restrictions of the COVID-19 pandemic, Farrell continued to ensure that patients had access to cutting-edge care.
Evaluating the current standards of care for cystectomy yielded interesting results on when it is most appropriate.
Jelmyto provides an alternative treatment option for low-grade UTUC and may spare some patients from nephrectomy. A recent study of the treatment showed a 58% complete response rate.
The COVID-19 pandemic has precipitated many changes in medical practice. View this symposium, where the Fox Chase Cancer Center genitourinary (GU) oncology team will discuss the impact of the pandemic on GU cancer care as well as the latest ...
Daniel Eun, MD, Fox Chase-Temple Urologic Institute Provider, discusses the management of complications in robot-assisted surgery.
Daniel Eun, MD and other Fox Chase-Temple Urologic Institiute Providers present a 72-year-old patient diagnosed with a left-sided distal ureteral stricture who undergoes a ureteral reimplantation.
Daniel Eun, MD, Fox Chase-Temple Urologic Institute Provider, discusses strategies for enabling complex robotic reconstruction of the upper urinary tract.
Daniel Eun, MD, Fox Chase-Temple Urologic Institute Provider, discusses the advantages and disadvantages of Robotic Retzius Sparing Simple Prostatectomy when compared to Holmium Laser Enucleation of the Prostate (HoLEP)
Daniel D. Eun, MD, Michael J. Metro, MD and other providers from the Fox Chase-Temple Urologic Institiute present a 38-year-old patient diagnosed with an iatrogenic bladder injury who undergoes a Ureterovaginal Fistual repair.
Temple robotic surgeons are making it possible for more patients to receive lifesaving therapies after being told they were out of options.
Fox Chase Cancer Center is now offering patients a more convenient and effective method of prostate cancer diagnosis—the ExactVu™ micro-ultrasound system.
The clinicians in Fox Chase Cancer Center’s Division of Urology and Urologic Oncology are accustomed to providing patients with specialized care and advanced treatment, but they are also dedicated to sharing their experience and educating ...
Viterbo brought her experience and expertise back to her practice at Fox Chase and, in the years since, has worked with colleagues in the Division of Urology and Urologic Oncology to pioneer the use of robotics in more and more cancer surgeries.
Throughout Susan Sippel’s career at Fox Chase, three things have stood out: mentors, connecting with patients, and teamwork. She joined Fox Chase 29 years ago as a ward secretary for the Three South unit after her sister-in-law, a Fox ...
New research from clinical investigators at Fox Chase may help men with prostate cancer in selecting the appropriate type of radiation therapy to treat their disease.
In a recent study, Fox Chase Cancer Center researchers sought to identify predictors of concern in men who recently underwent treatment for prostate cancer.
Robot-assisted renal surgery using retroperitoneal access requires substantial technical expertise and experience, and the urologic oncology team at Fox Chase Cancer Center is one of few local centers of excellence that offers it as a treatment option.
The urologic oncology team at Fox Chase Cancer Center continues to foster important international relationships in its pursuit of optimal surgical strategies for kidney cancer.
The NCCN and ASCO have developed new guidelines that describe which bodily systems can be affected by immunotherapy and how to manage side effects based on their severity.
Benjamin T. Ristau, MD, MHA, Randall A. Lee, MD, and Alexander Kutikov, MD, FACS, present a retroperitoneoscopic robot-assisted partial nephrectomy on a morbidly obese patient.
Over the last decade, dozens of predictive models have been developed to improve on the ability of stage, grade and type to predict recurrence. Unfortunately, many of the prediction models used by clinicians to guide patient care and clinical ...
Treatment approaches for bladder and prostate cancers have undergone rapid evolution in the last few years. Some patients can now safely delay or avoid surgery entirely and preserve their quality of life with positive oncological outcomes. ...
In a minimally invasive outpatient procedure, the two liquid components of SpaceOAR hydrogel are injected through the peritoneum (transperineally) into the space between the rectal wall and the prostate by a urologist. The procedure is ...